1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein
    + Filter
    Loading...
    Custom Services order now ship next day

    CD38

    Loading...

    Anti-CD38 Products

    More Infomation

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Leveraging our advanced platforms, Creative Biolabs provides full comprehensive, and high-quality CD38-targeted recombinant antibodies for clients around the world. We are committed to advancing research and discovery with exceptional value and unparalleled technical support, ensuring our clients achieve their scientific goals efficiently and effectively.

    CD38: A Prominent Target in Inflammatory Disease

    CD38 is a multifunctional ectoenzyme that plays a pivotal role in cellular signaling and immune responses. It facilitates the conversion of NAD+ to cyclic ADP-ribose (cADPR) and subsequently hydrolyzes cADPR to ADP-ribose. This enzyme becomes significantly upregulated during infections and inflammation, contributing to various inflammatory processes, transmembrane signaling, and cell adhesion. Due to its critical involvement in these mechanisms, CD38 is frequently used as a biomarker for inflammatory diseases such as leukemia and myeloma.

    Alternative Names

    Cluster Of Differentiation 38; CD38 molecule; CD38 Antigen; ADPRC1; ADP-Ribosyl Cyclase 1; Cyclic ADP-Ribose Hydrolase 1; 2-Phospho-ADP-Ribosyl Cyclase; Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase; NAD(+) Nucleosidase; 2-Phospho-Cyclic-ADP-Ribose Transferase; CADPr Hydrolase 1; T10

    Background

    CD38 (CD38 Molecule) is a Protein Coding gene. Diseases associated with CD38 include Richter's Syndrome and Leukemia, Chronic Lymphocytic. Among its related pathways are Cell-type Dependent Selectivity of CCK2R Signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. Gene Ontology (GO) annotations related to this gene include transferase activity and hydrolase activity, acting on glycosyl bonds.

    Anti-CD38 Recombinant Antibody Products

    Our mission is to boost research and innovation by offering premium anti-CD38 recombinant antibodies at exceptional value, coupled with top-notch technical support. The list below contains several anti-CD38 recombinant antibodies. For more information and to select the best option, please visit the link.

    Cat. No. Product Name Target Species Host Species Applications
    HPAB-0301-YC Human Anti-CD38 Recombinant Antibody Human, Cynomolgus Human IgG1 ELISA, FC, Cyt
    HPAB-0379-FY Mouse Anti-CD38 Recombinant Antibody (clone OKT10) Human Mouse IgG Cyt, Block, Activ
    HPAB-0470LY Mouse Anti-CD38 Recombinant Antibody (clone S5B5) Human Mouse IgG ELISA, Block
    HPAB-0134CQ Human Anti-CD38 Recombinant Antibody Human Human IgG1, λ ELISA, FC, ADCC, FuncS
    TAB-154LC Human Anti-CD38 Recombinant Antibody Cynomolgus, Human Human IgG1 ELISA, FC, IF, FuncS

    Creative Quality Control

    Our commitment is to empower the biopharmaceutical community by advancing research and development through unparalleled product quality and exceptional support. We prioritize customer satisfaction by rigorously maintaining a comprehensive quality management system. This ensures our products not only meet but surpass industry standards, thereby streamlining the drug development process and delivering superior value to our customers.

    Fig.1 WB analysis of HPAB-0134CQ. (Creative Biolabs Original)Fig.1 Anti-CD38 Recombinant Antibody in WB.
    (Cat# HPAB-0134CQ, Creative Biolabs).

    Fig.2 ELISA analysis of HPAB-0134CQ. (Creative Biolabs Original)Fig.2 Anti-CD38 Recombinant Antibody in ELISA.
    (Cat# HPAB-0134CQ, Creative Biolabs).

    Fig.3 SDS-PAGE analysis of HPAB-0134CQ. (Creative Biolabs Original)Fig.3 Anti-CD38 Therapeutic Antibody in SDS-PAGE. (Cat# HPAB-0134CQ. Creative Biolabs).

    Fig.4 HPLC analysis of HPAB-0379-FY. (Creative Biolabs Original)Fig.4 Anti-CD38 Recombinant Antibody in HPLC.
    (Cat# HPAB-0379-FY, Creative Biolabs).

    Fig.5 SDS-PAGE analysis of HPAB-0301-YC. (Creative Biolabs Original)Fig.5 Recombinant Anti-CD38 Antibody in SDS-PAGE.
    (Cat# HPAB-0301-YC, Creative Biolabs).

    Fig.6 Phycoerythrin Label Assay of HPAB-0301-YC. (Creative Biolabs Original)Fig.6 Recombinant Anti-CD38 Antibody Phycoerythrin Label Assay.
    (Cat# HPAB-0301-YC, Creative Biolabs).

    Customer Reviews

    Excellent
    Mart**a
    Human Anti-CD38 Recombinant Antibody (HPAB-0134CQ) (HPAB-0134CQ)
    I purchased this product for ADCC assay. Surprisingly, the purity and bioactivity of this product are exceptional, making it ideal for ADCC assay. Also, the pricing is competitive and the customer service is top-notch. I am thoroughly impressed with my purchase.
    18/Jan/2024
    Excellent
    N**k
    Human Anti-CD38 Recombinant Antibody; scFv Fragment (HPAB-0402-CN-S(P)) (HPAB-0402-CN-S(P))
    I recently acquired an antibody product from Creative Biolabs. In my preliminary experiments, I evaluated its specificity across various species' tissue samples. The outcomes confirmed its exceptional reactivity to human tissues and demonstrated its high sensitivity, as even minimal sample quantities elicited a notable reaction.
    5/Feb/2024
    Excellent
    Elo**a
    Human Anti-CD38 Recombinant Antibody (HPAB-1361LY) (HPAB-1361LY)
    I utilized this product to map the distribution of CD38 in human tissues and observed an impressive positive response when applied at the suggested concentration.
    26/May/2023

    Anti-CD38 Recombinant Antibody Production

    Our cutting-edge serum-free mammalian cell expression platform offers comprehensive services from gene synthesis to scalable, high-quality anti-CD38 recombinant antibody production. With over 5 years of expertise and experience in process optimization, we deliver fast and cost-effective solutions for rapid various quantities of antibody supply in a short turnaround.

    Featured Anti-CD38 Recombinant Antibody Production Platforms Fig.7 Anti-CD38 recombinant antibody production: milligram-scale. (Creative Biolabs Original)
    Fig.7 Milligram-scale anti-CD38 recombinant antibody production.

    Fig.8 Anti-CD38 recombinant antibody production: gram-scale. (Creative Biolabs Original)Fig.8 Gram-scale anti-CD38 recombinant antibody production.

    Anti-CD38 Recombinant Antibody Modalities

    Creative Biolabs is dedicated to delivering highly innovative and diverse recombinant antibodies to researchers. Our anti-CD38 recombinant antibodies include various formats such as full-length, Fab, scFv, etc. Leveraging our extensive expertise and experience in antibody engineering, we have the confidence and capacity to provide customized solutions to meet your specific research needs.

    Fig.9 Diverse anti-CD38 recombinant antibody production and modalities. (Creative Biolabs Original)Fig.9 Full-Length Anti-CD38 Recombinant Antibody Production and Modalities.

    CD38-Targeted Drug Information

    Table 1. CD38-targeted drug information.

    Company Research Phase Condition Indication
    Janssen Pharmaceutical (JP) Launched - 2017 Multiple myeloma Treatment of adults with relapsed or refractory multiple myeloma in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone; In combination with carfilzomib and dexamethasone, for the treatment of patients with recurrent or refractory multiple myeloma
    Janssen Registered - 2018 Multiple myeloma In combination with bortezomib, melphalan and prednisone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT)
    Janssen Phase III Multiple myeloma Treatment of pediatric and adult patients with multiple myeloma as monotherapy or in combination with carfilzomib, dexamethasone, lenalidomide and pomalidomide
    Mayo Clinic Phase II Glomerulonephritis, membranoproliferative Treatment of proliferative glomerulonephritis with monoclonal immune deposits and C3 glomerulopathy associated with monoclonal gammopathy
    Janssen Pharmaceutical (JP) Launched - 2021 Light chain amyloidosis In patients with newly diagnosed light-chain (AL) amyloidosis, in combination with cyclophosphamide, bortezomib and dexamethasone
    Sanofi Launched - 2020 Multiple myeloma Treatment of recurrent or refractory multiple myeloma, in combination with pomalidomide and dexamethasone
    Sanofi Registered - 2020 Multiple myeloma Treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy, in combination with pomalidomide and dexamethasone; In combination with carfilzomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy
    Sanofi Pre-Registered Multiple myeloma In combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM)
    Biocad Phase III Multiple myeloma As monotherapy in adults with relapsed and refractory multiple myeloma
    I-Mab Biopharma Phase III Multiple myeloma In patients with relapsed/refractory multiple myeloma who have received at least one prior line of therapy, in combination with lenalidomide and dexamethasone

    (Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

    Please contact us to learn more about our anti-CD38 recombinant antibody products. We are eager to explore opportunities for a mutually beneficial collaboration and help you advance your research.

    Go to compare

    Go to compare